ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder
BEL AIR, Md. and SAN FRANCISCO, May 14, 2024 /PRNewswire/ -- Amygdala Neurosciences (a private company) announced today that the Company has closed a new round of equity financing led by ABMRF, the Alcohol Beverage Medicines Research Foundation to fund the Company's IND-stage activities for ANS-858.
- ABMRF/The Foundation for Alcohol Research is the largest, independent non-profit foundation in North America devoted solely to funding research on the effects of alcohol on health and behavior ( https://www.abmrf.org/ ).
- Bruce Ambler, Chair Board of Trustees ABMRF said "Amygdala Neurosciences has established itself as a leader in the field of alcohol research.
- Craving is a key component of the alcohol use disorder adaptation, which consists of craving, loss of control, and adverse consequences.
- Amygdala Neuroscience's lead clinical candidate, ANS-858, targets the first of these aspects of the misuse of alcohol."